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Abstract
Background: The objective of this analysis is to explore potential impact on operating room (OR) efficiency and
incidence of residual neuromuscular blockade (RNMB) with use of sugammadex (Bridion™, Merck & Co., Inc., Kenilworth,
NJ USA) versus neostigmine for neuromuscular block reversal in Canada.
Methods: A discrete event simulation (DES) model was developed to compare ORs using either neostigmine or
sugammadex for NMB reversal over one month. Selected inputs included OR procedure and turnover times,
hospital policies for paid staff overtime and procedural cancellations due to OR time over-run, and reductions in
RNMB and associated complications with sugammadex use. Trials show sugammadex’s impact on OR time and
RNMB varies by whether full neuromuscular recovery (train-of-four ratio ≥0.9) is verified prior to extubation in
the OR. Scenarios were therefore evaluated reflecting varied assumptions for neuromuscular reversal practices.
Results: With use of moderate neuromuscular block, when full neuromuscular recovery is verified prior to extubation
(93 procedures performed with sugammadex, 91 with neostigmine), use of sugammadex versus neostigmine avoided
2.4 procedural cancellations due to OR time over-run and 33.5 h of paid staff overtime, while saving an average of
62 min per OR day. No difference was observed between comparators for these endpoints in the scenario when full
neuromuscular recovery was not verified prior to extubation, however, per procedure risk of RNMB at extubation was
reduced from 60% to 4% (reflecting 51 cases prevented), with associated reductions in risks of hypoxemia (12 cases
avoided) and upper airway obstruction (23 cases avoided).
Sugammadex impact in reversing deep neuromuscular block was evaluated in an exploratory analysis. When it was
hypothetically assumed that 30 min of OR time were saved per procedure, the number of paid hours of staff over-time
dropped from 84.1 to 32.0, with a 93% reduction in the per patient risk of residual blockade.
Conclusions: In clinical practice within Canada, for the majority of patients currently managed with moderate
neuromuscular block, the principal impact of substituting sugammadex for neostigmine is likely to be a reduction in
the risk of residual blockade and associated complications. For patients maintained at a deep level of block to the end
of the procedure, sugammadex is likely to both enhance OR efficiency and reduce residual block complications.
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Background
Neuromuscular blocking agents (NMBAs) are often ad-
ministered during surgical procedures to provide muscle
relaxation, and to prevent patient movement, which may
increase the risk of surgical complications. When neuro-
muscular block no longer needs to be maintained,
patients may either be allowed to spontaneously recover
neuromuscular function or be administered a reversal
agent for more rapid recovery. The acetylcholinesterase
inhibitor neostigmine is commonly used for reversal of
moderate neuromuscular blockade (e.g., when at least
the second twitch [T2] of a train-of-four stimulation is
present). Due to the occurrence of muscarinic side
effects with neostigmine such as nausea, vomiting and
bradycardia, it is typically co-administered with an anti-
muscarinic agent such as atropine or glycopyrrolate [1].
Recovery of neuromuscular function via either spontan-
eous reversal or use of neostigmine is neither rapid nor
of predictable duration [2, 3]. Patients may therefore be
inadvertently extubated while still experiencing residual
neuromuscular paralysis (residual neuromuscular block-
ade), with accompanying respiratory and muscular compli-
cations [4].
Sugammadex (Bridion™, Merck & Co., Inc., Kenilworth,
NJ USA, sponsor of the present analysis), a modified
gamma-cyclodextrin, is a more recently developed reversal
agent, recently approved for commercialization in Canada
(and also licensed in the United States and European
Union) to reverse neuromuscular blockade induced by the
NMBAs rocuronium or vecuronium [5]. In clinical trials,
sugammadex has been shown to produce much more
rapid and predictable reversal of neuromuscular block
than neostigmine, in the absence of anti-muscarinic side
effects and, in trials where quantitative neuromuscular
monitoring was not required, a steep reduction in the
incidence of residual neuromuscular blockade (RNMB)
[3, 5–8]. In addition, sugammadex is efficacious in
rapidly reversing deep neuromuscular block (i.e., at re-
appearance of 1–2 post-tetanic counts), [2, 9, 10]
whereas acetylcholinesterase inhibitors such as neostig-
mine cannot adequately reverse deep levels of blockade
because they reach a “ceiling” effect in which the
increase in acetylcholine concentration is insufficient to
displace enough NMBA molecules to reverse neuro-
muscular block [10, 11].
The objective of the present analysis is to explore
potential impact on operating room (OR) efficiency and
incidence of RNMB with use of sugammadex versus
neostigmine for routine reversal of neuromuscular
blockade in Canada. This paper describes a discrete
event simulation (DES) model developed for this pur-
pose. Outcomes explored include selected clinical events
associated with residual neuromuscular blockade and
OR efficiency-related measures.
Methods
Ethical committee approval was not required for the
present study as modeling was based on secondary data
sources and human or animal subjects were not
enrolled.
Perspective
The model perspective is that of a Canadian hospital. An
OR schedule and patient clinical outcomes associated
with neuromuscular blockade were simulated over a
1 month period (21 working days) for ORs utilizing
either sugammadex or neostigmine for neuromuscular
block reversal.
Treatment comparators
The primary analyses evaluate reversal of moderate
neuromuscular blockade, with sugammadex (2 mg/kg)
compared to neostigmine (50 μg/kg) plus glycopyrro-
late (10 μg/kg). Reversal of deep neuromuscular block
is evaluated as an exploratory analysis utilizing a
4 mg/kg dose of sugammadex. Neuromuscular block
was assumed to be maintained with either rocuronium
or vecuronium (though in Canada vecuronium is not
utilized), for which sugammadex is indicated for
reversal.
Acetylcholinesterase inhibitors such as neostigmine can-
not adequately reverse deep levels of blockade [10, 11]. In
clinical practice, for procedures utilizing deep block, the
level of neuromuscular blockade is generally allowed to
fade to moderate, prior to administering neostigmine. This
scenario was modeled as an exploratory analysis as there
has not been a corresponding clinical trial of sugammadex
to date in which all patients in the neostigmine arm were
administered deep block which was allowed to fade to
moderate prior to reversal agent administration, and
hypothetical values for potential time savings with sugam-
madex use were therefore evaluated.
Structure
The DES model was developed in part with Arena Version
14.7 software (Rockwell Automation, Milwaukee, WI),
with a Microsoft Excel 2010 (Redmond, WA) interface
used for input entry and output reporting. The model
compares ORs using either neostigmine or sugammadex
for NMB reversal, for the same simulated schedule of pro-
cedures performed daily on 21 working days over 1 month.
The impact of using sugammadex compared to neostig-
mine on OR procedure time (time from OR admission to
OR discharge) within clinical trials has varied according to
how neuromuscular recovery and extubation have been
managed [12–16]. Because neuromuscular recovery prac-
tices may vary by institution, the model therefore evalu-
ates a variety of different scenarios for the proportion of
patients (0%, 5%, 10%, 25%, 50%, 75%, 100%) verified
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to have full neuromuscular recovery (TOF ratio ≥ 0.9)
prior to extubation in the OR.
Random durations are generated for the OR proce-
dures utilizing the assumed mean duration for each pro-
cedure and its statistical distribution. Random values are
generated similarly for other parameters influencing
procedural flow, including time from the start of the OR
day to initiation of the 1st procedure, turnover times
between procedures, frequency of emergency procedures
(immediately inserted into the OR schedule bumping the
next scheduled procedure), frequency of semi-emergency
procedures (added on at the end of the OR day), probabil-
ity and impact of procedural cancellations due to reasons
other than OR time over-run and time for staff clean-up
of the OR at the end of the day. Additional model parame-
ters include hospital policies for procedural cancellation
when OR time over-run occurs, impact of sugammadex
on OR time per procedure compared to neostigmine, risk
of residual neuromuscular blockade and its clinical seque-
lae with neostigmine use and risk reductions with sugam-
madex and staff eligible for OR overtime pay. An overview
of the model structure is shown in Fig. 1 for OR proced-
ural flow and in Fig. 2 for residual neuromuscular block-
ade and associated complications.
The aforementioned parameters are used to esti-
mate sugammadex’s impact versus neostigmine on OR
times and procedural flow, staff overtime, procedural
cancellation and risk of residual neuromuscular block-
ade and associated complications.
Inputs
A series of systematic literature searches of the US
National Library of Medicine’s PubMed database (http://
www.ncbi.nlm.nih.gov/pubmed/) were conducted to ob-
tain data values for various model parameters. In addition,
to the PubMed database, the Cochrane Library and
University of York and Centre for Reviews and Dissemin-
ation (CRD) databases were also searched. Reference lists
within publications of potential relevance were further
searched to identify additional studies. Proprietary infor-
mational sources providing relevant data were also
reviewed. For conciseness, the specific PubMed literature
search strategies for each model input are described in
detail in Additional file 1. PubMed searches were con-
ducted for literature published up to August 21, 2015.
For operating room scheduling and staffing parameters
(e.g., time to start of OR day, turnover times, time for OR
clean-up, procedure duration, OR staff eligible for over-
time pay), values would expected to be highly variable
across operating rooms and institutions. With respect to
scheduling, available publications reporting data often
reflect examples where efficiency was less than desired
and improvements were sought. Rather than conducting a
formal meta-analysis across publications, data from avail-
able sources deemed as reasonable and credible by OR
experts were included within the model and values were
varied in reported sensitivity analyses.
In clinical practice, parameters for the OR day and
procedural flow vary by hospital and OR. Illustrative
examples of parameter values for these variables were
gathered from the literature or based on assumption as
described in Table 1. Estimation methods for other indi-
vidual model parameters are described in greater detail
within this section.
Impact of sugammadex vs. neostigmine on OR procedure
time
Published clinical trials comparing sugammadex to neo-
stigmine have typically reported information on time
from administration of the reversal agent to full patient
neuromuscular recovery to a TOF ratio of ≥ 0.9, mea-
sured via quantitative neuromuscular monitoring [17].
Fig. 1 Diagram of operating room day and procedural flow
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This is the preferred endpoint for evaluating sugamma-
dex’s efficacy with respect to accelerating neuromuscular
recovery, consistent with the direct impact of usage. How-
ever, of interest with respect to the present modeling, is
the impact of accelerated neuromuscular recovery on the
downstream endpoint of patient time in the OR. Compari-
sons between sugammadex and neostigmine of time from
reversal agent administration to full neuromuscular re-
covery often do not well correlate with impact on over-
all OR time for several reasons.
First, in clinical practice, patients are often discharged
from the OR prior to achieving full neuromuscular re-
covery, while residual neuromuscular blockade (TOF
ratio < 0.9) is present [4, 18]. Second, even where
patients have full neuromuscular recovery in the OR,
that may not be a rate-limiting step to OR discharge if
other necessary activities (e.g., wound suturing, medical
equipment removal) occur during this time period cur-
rently with use of neostigmine, the time for which cannot
be fully eliminated with accelerated neuromuscular recov-
ery. Third, in clinical practice, recognizing the much
shorter time to full neuromuscular recovery with sugam-
madex versus neostigmine, [17] the products may be ad-
ministered at different time points within a procedure
(neostigmine earlier due to longer lead-time needed for an
effect and sugammadex later due to very rapid effect in re-
versing moderate block, and sugammadex earlier and neo-
stigmine later in procedures ending in deep block). As a
result, the shortened reversal time with sugammadex
would not translate to a commensurate reduction in time
to OR discharge. Thus, neuromuscular recovery time is
likely to correlate least with patient time in the OR in pro-
cedures where there is not full neuromuscular recovery
(TOF ratio ≥ 0.9) prior to extubation in the OR, or where
deep block is maintained through the end of the proced-
ure, with the potential for a somewhat greater correlation
in procedures utilizing a moderate level of block where
patients are maintained in the OR through full neuromus-
cular recovery.
Data were therefore analyzed from available clinical trials
reporting time from the endpoint of patient OR admission
to OR discharge for subjects randomized to receive sugam-
madex or neostigmine (Table 2). This endpoint directly
corresponds to patient time spent in the OR as evaluated
within the DES model. Results were stratified by whether
patients in the trial were verified to have full neuromuscular
recovery (TOF ratio ≥ 0.9) prior to extubation in the OR, as
the impact of sugammadex on OR time has been found to
vary according to how neuromuscular recovery is managed.
Specifically, larger and statistically significant OR time
savings with sugammadex use have been observed in trials
where all patients were “verified” to have full neuromuscu-
lar recovery (train-of-four [TOF] ratio ≥ 0.9) prior to extu-
bation via quantitative neuromuscular monitoring, whereas
time savings have either not been observed or not achieved
statistical significance in trials where verification of full
neuromuscular recovery was not required [12–16]. Avail-
able data were insufficient for further stratification by use
of rocuronium vs. vecuronium as the NMBA, or depth of
neuromuscular block throughout the procedure or at rever-
sal. Results across trials within each stratified group were
pooled via a random effects meta-analysis.
Risk of residual blockade at extubation and associated
efficacy of sugammadex
A statistically significant reduction in the incidence of
residual neuromuscular blockade at extubation with use
of sugammadex versus neostigmine has been demon-
strated in a randomized clinical trial where patients were
not required to have verification of full neuromuscular
recovery prior to extubation in the OR [6]. As additional
studies have also reported a risk of residual blockade
(TOF < 0.9) at extubation with neostigmine use, a litera-
ture search was conducted to estimate the background
risk of residual blockade.
Studies describing the risk of residual blockade at extu-
bation exclusively with rocuronium or vecuronium and
neostigmine use were gathered from the literature based
on two review articles, [4, 18] and a search of the PubMed
database using terms of “residual blockade”, “residual
block” or “curarization” for studies published from January
1, 2008 (updating from the literature canvassed in the re-
view articles) up to July 10, 2015. Studies using quantita-
tive neuromuscular monitoring to determine the time
point for extubation were excluded. Three studies meeting
review eligibility criteria were identified and meta-analyzed
Fig. 2 Model structure for reduction in risk of residual neuromuscular blockade and associated complications
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[6, 19, 20]. Rocuronium was used within each of the stud-
ies, and corresponding data were not found for patients
receiving vecuronium. However, vecuronium is not uti-
lized within Canada. The resultant average risk of residual
block at extubation with neostigmine use was estimated to
be 60% when patients are not required to have verifica-
tion of full neuromuscular recovery (TOF ratio ≤ 0.9) prior
to extubation in the OR. Additional details on the estima-
tion are provided in Additional file 1.
The efficacy of sugammadex in preventing residual
blockade, specified as a reduction in the risk of residual
blockade at extubation with sugammadex usage (93% re-
duction) compared to neostigmine, was estimated based
on data from the aforementioned randomized trial [6].
Table 1 Base case model inputs
Parameter Default valuea Source
Time Horizon 1 month (21 working days) Assumption
Operating Room
Start of OR day 7:30 AM Assumption
End of OR day 4:00 PM Assumption
Time from start of OR day to OR admission of first patient 10 min [36]
Time between procedures (turnover time) 35.6 min [37]
Time for OR clean-up/prep for next day 15 min Assumption
Procedure
Number of procedures per day 5 Assumption
Mean time per procedure with neostigmine use 72.9 min Analysis of RECITE Canada data
(data on file)
Probability of cancellation of schedule procedure (unrelated to OR time
over-run)
10.7% [38]
Is next procedure moved up when cancellation occurs? No Assumption
Can a procedure be cancelled because there is not enough OR time
available?
Yes Assumption
Cancellation policy No procedures may begin
after end of OR day
Assumption
Probability of emergency procedure insertion 0% Assumption
Probability of semi-emergency procedure insertion 0% Assumption
Residual Neuromuscular Block
Risk of residual block at extubation with neostigmine use 60.0% [6, 19, 20]
Absolute excess risk of hypoxemia with residual block 24.5% [33]
Absolute excess risk of upper airway obstruction with residual block 44.2% [6, 32]
Impact of Sugammadex vs. Neostigmine
Reduction in time from patient OR admission to OR discharge
All patients verified to have full neuromuscular recovery (TOF ratio ≥0.9)
prior to extubation in the OR
14 min Grintescu et al. 2009 [16]; P318 2010 [13]
No patients verified to have full neuromuscular recovery (TOF ratio ≥0.9)
prior to extubation in the OR
0 min P334 2009 [12]; P07981 2013 [14]; P07038
2014 [15]
Reduction in risk of residual neuromuscular blockade at extubation, among
patients not verified to have full neuromuscular recovery (TOF ratio ≥0.9)
prior to extubation
93% [6]
OR Staff Eligible for Overtime Pay
Registered nurses 3 present Assumption
Respiratory therapist 1 present Assumption
Nurse aide 1 present Assumption
Overtime pay policy 30 min increments Assumption
OR Operating room
aAssumed Arena probability distributions [Mean time per procedure with neostigmine use (LOGN 72.9,29.2); Turnover time (10+EXPO{25.6}); Time to OR admission
of 1st patient (DISC{0.5,5,1,15});OR clean-up time (TRIA{7.5,15,22.5})]
Insinga et al. BMC Anesthesiology  (2016) 16:114 Page 5 of 12
Risk of clinical sequelae of residual blockade
Clinical sequelae of residual blockade may include post-
operative aspiration, hypoxemia, muscle weakness and
upper airway obstruction.
In the case of aspiration, aspiration pneumonitis (and
atelectasis) have been reported as potential outcomes of
residual blockade [4, 21]. However, an elevated risk of
their occurrence has been observed with long-acting
NMBAs, but not with the intermediate-acting NMBAs
modeled in this analysis [22] and, to date, a reduction in
their incidence with sugammadex use has not been
found [23, 24]. Therefore, these clinical events were not
modeled as residual blockade outcomes. Uncomplicated
aspiration, occurring to the level of, or above, the vocal
cords has been reported in volunteer studies with TOF
ratios < 0.9, but not below the vocal cords. Due to the
rare documentation of aspiration during the post-
extubation and recovery periods in general anesthetic
settings, [25–27] and likely silent nature of events with
lack of clinical management, aspiration was not modeled
within the DES.
Muscle weakness, which may be characterized by general
weakness, as well as difficulty with speaking and vision, is
not uncommon post-operatively [21, 28], and occurs with
greater frequency among patients with residual neuromus-
cular blockade [28, 29]. However, no studies could be iden-
tified documenting an excess cost associated with post-
operative muscle weakness, nor did clinician consultation
suggest this to be a major contributor to resource use.
Therefore muscle weakness was also not modeled within
the DES.
Published literature were available from which to con-
struct estimates of the excess risk of hypoxemia and upper
airway obstruction associated with the occurrence of
residual neuromuscular blockade as reported in Table 1.
As the estimation methods are fairly detailed, the deriv-
ation of these values is described in Additional file 1.
Reversal agent resource use
Consistent with prior Canadian health technology assess-
ments (HTAs) and a UK National Institute for Health
Research (NIHR) HTA, an average patient weight of 75 kg
was assumed, with vial wastage [30]. Consistent with clin-
ical trials evaluating sugammadex, it is assumed that a
50 μg/kg dose of neostigmine is administered, in combin-
ation with a 10 μg/kg dose of glycopyrrolate. For sugamma-
dex, it is assumed that doses of 2 mg/kg and 4 mg/kg are
used to reverse moderate and deep block, respectively.
Operating room overtime resource use
When OR procedures run over the regular OR day, it is
assumed that, among the OR staff, registered nurses,
respiratory therapists and nurse aides are eligible for
overtime pay. Over-time is assumed to be paid in
30 min increments, rounded up to the nearest half hour.
It is assumed that 3 registered nurses, one nurse aide
and one respiratory therapist are present in a given OR.
Outputs
Model outputs for an OR, reported over a one month
time horizon with respect to use of sugammadex versus
neostigmine, include the number of procedures per-
formed, procedural cancellations due to regular OR day
over-run, hours of OR staff overtime and cases and com-
plications of residual blockade avoided. Other primary
outputs include the number of OR minutes saved per
day, % of days all procedures are completed within the
regular OR day and reduction in risk of RNMB. Each set
Table 2 Sugammadex impact vs. neostigmine on time from patient OR admission to OR discharge, per procedure
A. Trials Requiring Verificationa of Full Neuromuscular Recovery (TOF ratio≥ 0.9) Prior to Extubation in the OR
Sugammadex Arm Neostigmine Arm
N Minutes from OR admission to discharge N Minutes from OR admission to discharge SugammadexTime Savings P-value Source
17 64 17 80 16 0.04 [16]
66 b 158 64 169 11 0.23 [13]
83 81 14 0.02 Meta-analysis
B. Trials Not Requiring Verification of Full Neuromuscular Recovery Prior to Extubation in the OR
Sugammadex Arm Neostigmine Arm
N Minutes from OR admission to discharge N Minutes from OR admission to discharge SugammadexTime Savings P-value Source
48 183 46 167 −16 0.22 [12]
290 167 315 167 0 NA [15]
74 b 242 77 253 11 0.40 [14]
412 438 −1 0.89 Meta-analysis
NA Not applicable OR Operating room, TOF Train-of-four
aVerification of full neuromuscular recovery (TOF ratio ≥ 0.9) based on quantitative neuromuscular monitoring bNumbers below this row reflect a pooling of data
via meta-analysis
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of outputs is reported under various scenarios for the %
of patients verified to have full neuromuscular recovery
(TOF ratio ≥ 0.9) prior to extubation in the OR.
Sensitivity analyses
Illustrative sensitivity analyses are reported varying the
assumed policy for cancelling a procedure due to lack of
OR time (cancel if < 50% of procedure can be completed
within the regular OR day, never cancel), whether the
next procedure is moved up when cancelling (fully move
up next procedure), the proportion of procedures in OR
which are emergency procedures (15%) and at 95% con-
fidence interval values for sugammadex OR time savings
per procedure versus neostigmine.
Exploratory analysis
An exploratory analysis is conducted evaluating results for
the 4 mg/kg dose of sugammadex in reversing patients
who are maintained at a deep level of neuromuscular
block until the end of the procedure. Sugammadex is effi-
cacious in rapidly reversing deep neuromuscular block
(i.e., at re-appearance of 1–2 post-tetanic counts), [2, 10]
whereas acetylcholinesterase inhibitors such as neostig-
mine cannot adequately reverse deep levels of blockade
because they reach a “ceiling” in which the increase in
acetylcholine concentration is insufficient to displace
enough NMBA molecules to reverse neuromuscular block
[10, 11]. For these patients in clinical practice, anesthesiol-
ogists wait until the depth of block has faded to a moder-
ate level after the completion of the procedure before
administering neostigmine. There has not been a corre-
sponding clinical trial of sugammadex to date in which all
patients in the neostigmine arm were administered deep
block through the end of the procedure, which was
allowed to fade to moderate block prior to reversal agent
administration. Therefore, hypothetical OR time savings
per procedure with sugammadex use of 15, 30, 45 and
60 min were explored.
Because the anesthesiologist must wait to reverse with
neostigmine until the depth of block has faded from
deep to moderate, it was implicitly assumed based on
expert feedback that the procedures would be longer
than in the base case when moderate block is used. To
achieve an OR schedule of identical average expected
duration as in the base case, it was assumed that 3 pro-
cedures of 145 min each, utilizing deep block to the end
of the procedure, would be scheduled per OR day.
Simulation
To allow for variability within the OR schedule across
OR days, procedure times were drawn from a lognormal
distribution around mean values, with discrete, exponen-
tial and triangular distributions within ARENA used to
draw values for time to first procedure start, turnover
times and time for OR clean-up/next day prep, respect-
ively. As point estimate values are varied within the
model, a fixed “variability ratio” was chosen for each of
the distributions, so that the standard deviation was ad-
justed according to the mean value entered. The model
was run with 50 replications within each analysis, repre-
senting 1050 simulated OR days, upon which results
converged to stable values.
Results
Primary analyses
Comparison of sugammadex and neostigmine in the
reversal of moderate neuromuscular block with respect
to OR efficiency and clinical outcomes in an OR over a
1 month period is reported in Table 3. The estimated
average number of OR minutes saved per day with
sugammadex use varies from 0 to 62 min as the percent-
age of patients verified to have full neuromuscular
recovery (TOF ratio ≥ 0.9) prior to extubation in the OR
is varied between 0 and 100%. Correspondingly, the
percent of days all procedures are completed within the
regular OR day with sugammadex use varies from
40.6% (equivalent to with neostigmine use) up to 72.7%,
when the percentage of patients verified to have full re-
covery in the OR is varied from 0 to 100%. Depending
on the proportion of patients verified to have full re-
covery in the OR, the number of procedures performed
over 1 month may be increased (range of 0 to 2.2 add-
itional procedures), and number of procedures can-
celled due to lack of OR time (range of 0 to 2.4
cancelled procedures avoided) and paid hours of staff
over-time decreased with sugammadex use (range of 0
to 33.5 fewer hours).
The impact of sugammadex upon clinical outcomes of
RNMB exhibits an opposite trend with respect to neuro-
muscular recovery practices. The number of cases of
residual blockade avoided with sugammadex decreases
from 51 to 0 as the percent of patients verified to have
full recovery in the OR increases from 0 to 100%, with
an absolute reduction in the risk of residual blockade
per patient ranging from 56 to 0%. In the scenario
where 0% of patients were verified to have full neuro-
muscular recovery prior to extubation, the numbers
needed to treat (NNT) to prevent a case of residual
blockade, hypoxemia and upper airway obstruction
were 1.8, 7.6 and 3.9, respectively. The NNTs increase
as a higher % of patients are verified to have full neuro-
muscular recovery.
Sensitivity analyses
Prior work has found OR resource use and costs with
sugammadex use to be much less sensitive to offsets associ-
ated with residual blockade as compared to OR staff time/
over-time [31]. It was therefore elected for illustrative
Insinga et al. BMC Anesthesiology  (2016) 16:114 Page 7 of 12
purposes to focus the sensitivity analyses upon the scenario
where 100% of patients are verified to have full neuromus-
cular recovery (TOF ratio ≥ 0.9) in the OR prior to extuba-
tion, as OR staff over-time is most influential within this
scenario (Table 4).
In the primary analyses, it is assumed that no procedures
may begin after the end of the regular OR day and are
otherwise cancelled. When this is modified to assume that
cancellation occurs if <50% of the anticipated duration of a
procedure may be completed within the regular OR day (a
relatively lower threshold for cancelling), the number of
procedural cancellations avoided with sugammadex use
increases, with a smaller absolute reduction in staff over-
time hours. In contrast, if it is assumed that a procedure
can never be cancelled due to a lack of OR time, the
reduction in paid hours of staff over-time with sugamma-
dex use nearly doubles as compared to within the primary
analyses.
If it is assumed that 15% of procedures are emergency
cases (as opposed to 0% in the primary analyses), which
bump scheduled cases, the number of procedures can-
celled due to lack of OR time and paid hours of staff over-
time increase dramatically, with relatively larger absolute
reductions in these outcomes with sugammadex use as
compared to in the primary analyses.
Results were also sensitive to assumed OR time sav-
ings with sugammadex versus neostigmine, when
varied across values for the 95% confidence interval
for this parameter (2 to 26 min) as observed within
pooled clinical trial data.
Exploratory analyses
In the exploratory analyses (Table 5), it is assumed
that patients are maintained at a deep level of neuro-
muscular block through the end of the procedure and
reversed with neostigmine or a 4 mg/kg dose of
sugammadex. As described in the Methods section, as
the amount of time saved with sugammadex versus
neostigmine in clinical practice in these patients is un-
known, hypothetical time savings of 15, 30, 45 and
60 min per procedure are explored. When the amount
of OR time saved is fixed, the percentage of patients
verified to have full neuromuscular recovery in the OR
no longer influences sugammadex’s impact upon OR
time within the analysis. For illustrative purposes, it
was therefore elected to conduct the exploratory ana-
lysis for the scenario where 0% of patients are verified
to have full neuromuscular recovery in the OR, as re-
sults would be very similar for the other scenarios,
with the exception of the incidence of clinical out-
comes of residual blockade.
In the deep block analysis, as the number of mi-
nutes of OR time saved per procedure with sugamma-
dex increases, the number of procedures cancelled
due to a lack of OR time decreases, along with paid
hours of staff over-time. For instance, the number of
paid hours of staff over-time drops from 84.1 to 32.0,
when 30 min of OR time are saved per procedure.
The number of paid hours of staff over-time with
neostigmine use is greater than in the model base
case due to the impact of the assumed increased
Table 3 Comparison of sugammadex and neostigmine on OR efficiency and clinical outcomes in an OR over 1 month in the
reversal of moderate neuromuscular block
Outcome Measure Neostigmine Sugammadex (2 mg/kg)
% of patients verified to have full neuromuscular recovery
(TOF ratio≥ 0.9) prior to extubation
0% 5% 10% 25% 50% 75% 100%
OR efficiency outcomes
Number of OR minutes saved per day – 0 3 6 15 31 46 62
% of days all procedures are completed within the regular OR day 40.6% 40.6% 40.8% 42.7% 49.0% 58.0% 65.0% 72.7%
Number of procedures performed 90.8 90.8 90.9 91.0 91.6 92.5 92.9 93.0
Procedures cancelled due to lack of OR time 3.5 3.5 3.4 3.3 2.8 1.9 1.4 1.1
Procedures cancelled for other reasons 10.7 10.7 10.7 10.8 10.7 10.6 10.8 11.0
Paid hours of staff over-time 57.8 57.8 57.4 54.9 47.9 38.9 31.9 24.3
Clinical outcomes
Cases of residual blockade avoided – 51 48 46 38 25 13 0
Hypoxemia cases avoideda – 12 12 11 9 6 3 0
Upper airway obstruction cases avoideda – 23 21 20 17 11 6 0
Absolute reduction in risk of residual blockade, per patient – 56% 53% 50% 42% 28% 14% 0%
OR Operating room
aIncludes both cases which are and are not clinically diagnosed and managed
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variability in the duration of the procedures for the
longer deep block procedures as compared to the
shorter moderate block procedures.
Discussion
This analysis has shown that, depending upon the neuro-
muscular management and extubation practices at a given
hospital, sugammadex can potentially reduce the risk of
RNMB and/or enhance operating room efficiency.
For procedures ending with moderate neuromuscular
block, when patients are not verified to have full neuro-
muscular recovery (TOF ratio ≥ 0.9) prior to extubation
in the OR, use of neostigmine results in a high incidence
of RNMB [6], with associated clinical complications of
upper airway obstruction and hypoxemia [32, 33]. To
avoid these risks of respiratory complications, if patients
administered neostigmine are maintained in the OR
until full neuromuscular recovery is verified and they
may be safely extubated, additional time is expended
within the OR [13, 16]. Sugammadex can ameliorate
this trade-off between OR efficiency and the occur-
rence of residual neuromuscular block by substantially
accelerating the time to complete neuromuscular re-
covery [17] and safe extubation.
When patients are maintained with deep neuromuscular
block to the end of the procedure, sugammadex is very
likely to save time in the OR compared to neostigmine
use, with reductions in the risk of RNMB dependent upon
whether patients are verified to have full neuromuscular
recovery (TOF ratio ≥ 0.9) prior to extubation in the OR.
In clinical practice, patients currently are rarely verified
to have full neuromuscular recovery (TOF ratio ≥ 0.9)
prior to extubation in the OR as evidenced by low use of
quantitative neuromuscular monitoring [34, 35] and high
incidences of RNMB with neostigmine use [6, 19, 20].
Thus, for the majority of patients currently managed with
moderate neuromuscular block in Canada, the principal
impact of the substitution of sugammadex for neostigmine
is likely to be a reduction in the risk of residual blockade
and associated complications. Under these conditions, for
patients managed with deep neuromuscular block through
the end of the procedure, sugammadex is expected to both
reduce OR procedure times and complications associated
with residual blockade relative to use of neostigmine.
Table 4 Sensitivity Analyses - For scenario where 100% of patients are verified to have full neuromuscular recovery (TOF ratio≥ 0.9)
prior to extubation in the OR
Number of OR minutes saved per day % of days all procedures are
completed within the regular OR day
Procedures cancelled




Neostigmine – 40.6% 3.5 57.8
Sugammadex 62 72.7% 1.1 24.3
Cancel if < 50% of procedures can be completed within the regular OR day
Neostigmine – 39.5% 6.8 36.0
Sugammadex 62 73.7% 1.9 16.5
Never cancel a procedure due to lack of OR time
Neostigmine – 40.4% 0.0 92.0
Sugammadex 63 74.3% 0.0 31.4
Fully move up next procedure if a cancellation occurs
Neostigmine – 63.2% 2.4 32.3
Sugammadex 62 85.2% 0.7 12.9
Assume 15% of procedures are emergency cases
Neostigmine – 19.8% 16.1 108.5
Sugammadex 57 45.0% 9.6 66.6
Sugammadex OR time saved at lower bound of 95% CI in trials (2 min)
Neostigmine – 40.6% 3.5 57.8
Sugammadex 9 44.9% 2.8 54.0
Sugammadex OR time saved at lower bound of 95% CI in trials (26 min)
Neostigmine – 40.6% 3.5 57.8
Sugammadex 116 92.2% 0.3 5.8
CI Confidence interval OR Operating room
aIn the primary analysis, procedures are cancelled if they cannot begin within the regular OR day, when a procedure is cancelled for any reason, the next
procedure is not moved up, and no emergency cases occur
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In interpreting the magnitude of OR time saved,
avoided procedural cancellations, avoided staff overtime
and avoided residual block, where applicable, within the
present analysis, a number of caveats should be kept in
mind. First, given the running time of the DES model to
complete iterations for the base case, it was prohibitive
to run a formal probabilistic sensitivity analysis (PSA)
across model parameters. However, most of the model
parameters for which results are most sensitive, as
described in the Results section, are based on different
scenario-based assumptions for quantitative neuromus-
cular monitoring, hospital cancellation and emergency
procedure policies. These types of parameters are best
explored in the one-way sensitivity analyses currently
performed within the analysis, as they are not amenable
to PSA.
Second, for illustrative purposes, it was assumed that all
procedures within the OR day used NMBAs of rocuro-
nium or vecuronium, and neostigmine or sugammadex
for neuromuscular reversal. This assumption enables full
evaluation of the potential for sugammadex to impact OR
time-related outcomes. In clinical practice, however, there
may be variation across procedures occurring within a
given OR on a particular day in terms of whether NMBAs
are used and, if so, whether neuromuscular block is
reversed using a pharmaceutical agent, or allowed to
spontaneously reverse. In ORs where this variation occurs,
the total potential impact of sugammadex on outcomes
related to OR time savings and residual block avoidance
would be lessened. Also, the primary analysis has modeled
5 short procedures of 72.9 min each. For ORs where 2–3
longer procedures are performed within a given day, all
else equal, the potential OR time savings and number of
residual blockade cases prevented by sugammadex are
also likely to be relatively less.
However, the resource use impact of OR time savings
within the present analysis, which was limited to those
staff members earning over-time pay due to OR time
over-run, is likely to only partially account for the bene-
fits to a hospital. One could also consider the intangible
value of time saved for salaried OR staff members who
are ineligible for over-time pay (e.g., surgeon and
anesthesiologist) as well as non-overtime minutes saved
for all OR staff members. Furthermore, when cancelled
procedures are avoided, there are potentially impacts for
the hospital and patient related to rescheduling, re-
preparation for the procedure and patient time/work
loss. Finally, if enough OR time saved can be accrued
within a given day, and the OR is running at full capacity
throughout the year, and there is a queue for procedures
or opportunity to expand the demand for OR proce-
dures, hospitals may be able to increase annual proced-
ural throughput and decrease surgical waiting times.
The impact of clinical sequelae of residual blockade is
a relatively under-researched area. It is important to
note that available literature were insufficient for identi-
fying where excess hospital resource use is incurred for
rarer but more serious respiratory outcomes which
could potentially occur (e.g., post-operative myocardial
infarction in cardiovascular disease patients, aspiration
pneumonia in emergency cases where patients are un-
able to be operated on with an empty stomach). Further
Table 5 Exploratory analyses - Comparison of sugammadex and neostigmine on OR efficiency and clinical outcomes in an OR over
1 month when deep block is maintained to the end of all procedures [0% of patients verified to have full neuromuscular recovery
(TOF ratio ≥ 0.9) prior to extubation]
Outcome Measure Neostigmine Sugammadex (4 mg/kg)
Minutes of OR time saved per procedure
15 30 45 60
OR efficiency outcomes
Number of OR minutes saved per day – 39 79 118 158
% of days all procedures are completed within the regular OR day 46.7% 61.9% 77.1% 86.9% 91.4%
Number of procedures performed 54.5 54.7 55.1 55.1 55.2
Procedures cancelled due to lack of OR time 1.2 0.7 0.4 0.4 0.3
Procedures cancelled for other reasons 7.3 7.6 7.6 7.6 7.6
Paid hours of staff over-time 84.1 54.9 32.0 18.3 11.5
Clinical outcomes
Cases of residual blockade avoided – 30 30 30 30
Hypoxemia cases avoideda – 7 7 7 7
Upper airway obstruction cases avoideda – 13 13 13 13
Absolute reduction in risk of residual blockade, per patient – 56% 56% 56% 56%
OR Operating room
aIncludes both cases which are and are not clinically diagnosed and managed
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research is needed to better understand the degree to
which these rarer clinical events are linked to residual
block and potentially avoidable with sugammadex use. It
is evident, however, that both residual blockade and its
sequelae are very common in the OR and PACU, with
an estimated risk of residual blockade at extubation of
60% with neostigmine use as reported herein [6, 19, 20].
Conclusions
Sugammadex can potentially reduce the risk of RNMB,
and/or enhance operating room efficiency, relative to
use of neostigmine for routine reversal of neuromus-
cular block. In clinical practice within Canada, for the
majority of patients currently managed with moderate
neuromuscular block, the principal impact of using
sugammadex instead of neostigmine is likely to be a
reduction in the risk of residual blockade and associ-
ated complications. For patients maintained at a deep
level of block to the end of the procedure, sugamma-
dex is likely to both enhance OR efficiency and reduce
complications of residual block. Where OR efficiency
gains occur, potential benefits of sugammadex may
include reduced procedural cancellations due to OR
time over-run, avoided staff over-time and opportunity
to evaluate if procedural throughput may be increased.
Additional file
Additional file 1: Additional details on estimation of selected model
input values. (DOC 96 kb)
Acknowledgments
The authors would like to thank André Jacques, Trellisys Technologies, Inc.
(Montreal, Canada) who provided support in the construction of the DES
model. We also thank Susan Grant and Eric Lefrançois of Merck Canada and
Jonathan Schelfhout of Merck U.S. for helpful input into earlier versions of
the model.
Funding
The authors completed this work as employees of Merck & Co., Inc., which
supported the publication charges for this manuscript.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article and its Additional file 1.
Authors’ contributions
RPI, CJ, AG and AG contributed to the design of the DES model. The initial
manuscript draft was developed by RPI with input from CJ. All authors have
read, provided input to and approved the final manuscript.
Competing interests




Ethics approval and consent to participate
Not applicable.
Author details
1Department of Predictive & Economic Modeling, Merck & Co., Inc, PO Box
1000, UG1CD-32, North Wales, PA 19454-1099, USA. 2Department of Health
Economics and Observational Research, 16750 Transcanada Highway, Merck
Canada, Kirkland, Québec H9H 4M7, Canada. 3Department of Medical Affairs,
16750 Transcanada Highway, Merck Canada, Kirkland, Québec H9H 4M7,
Canada.
Received: 10 September 2015 Accepted: 8 November 2016
References
1. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth.
2009;103:115–29.
2. A randomized, safety-assessor blinded trial comparing 4.0 Mg.Kg-1
Sugammadex with placebo in adult subjects scheduled for surgery
requiring profound neuromuscular blockade. Clinical Trial Report on
Protocol 19.4.316. Merck & Co., Inc. 2010.
3. Blobner M, Eriksson LI, Scholz J, Motsch J, Della RG, Prins ME. Reversal of
rocuronium-induced neuromuscular blockade with sugammadex compared
with neostigmine during sevoflurane anaesthesia: results of a randomised,
controlled trial. Eur J Anaesthesiol. 2010;27:874–81.
4. Murphy GS, Brull SJ. Residual neuromuscular block: lessons unlearned. Part I:
definitions, incidence, and adverse physiologic effects of residual
neuromuscular block. Anesth Analg. 2010;111:120–8.
5. Rex C, Bergner UA, Puhringer FK. Sugammadex: a selective relaxant-binding
agent providing rapid reversal. Curr Opin Anaesthesiol. 2010;23:461–5.
6. Sabo D, Jones RK, Berry J, Sloan T, Chen JY, Morte JB, Groudine S. Residual
neuromuscular blockade at extubation: a randomized comparison of
sugammadex and neostigmine reversal of rocuronium-induced blockade in
patients undergoing abdominal surgery. J Anesthes Clin Res. 2011;2:140.
7. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L,
Giunta FG, Meistelman C, Prins ME. Reversal of rocuronium-induced
neuromuscular block with sugammadex is faster than reversal of
cisatracurium-induced block with neostigmine. Br J Anaesth. 2008;100:622–30.
8. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H,
Alvarez-Gomez JA. Sugammadex provides faster reversal of vecuronium-
induced neuromuscular blockade compared with neostigmine: a
multicenter, randomized, controlled trial. Anesth Analg. 2010;110:64–73.
9. Geldner G, Niskanen M, Laurila P, Mizikov V, Hubler M, Beck G, Rietbergen H,
Nicolayenko E. A randomised controlled trial comparing sugammadex and
neostigmine at different depths of neuromuscular blockade in patients
undergoing laparoscopic surgery. Anaesthesia. 2012;67:991–8.
10. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-
induced blockade with sugammadex: a randomized comparison with
neostigmine. Anesthesiology. 2008;109:816–24.
11. Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice.
Drugs. 2009;69:919–42.
12. A multi-center, randomized, parallel group, comparative, active controlled,
safety assessor blinded, anesthesiologist-TOF-Watch® SX blinded trial
comparing T4/T1 ratio at time of tracheal extubation using 4 mg.kg-1
sugammadex administered at 1–2 PTCs or better after the last dose of
rocuronium bromide to 50 ?g.kg-1 neostigmine administered as per
standard of care in adult subjects undergoing elective open abdominal
procedures requiring neuromuscular blockade reversal. Clinical Trial Report
on Protocol 19.4.334. Merck & Co., Inc. 2009.
13. A multi-center, randomized, parallel group, comparative, active controlled,
safety assessor blinded trial in adult subjects comparing the efficacy and
safety of sugammadex (SCH 900616, ORG 25969) administered at 1–2 PTC
with neostigmine administered at reappearance of T2 in subjects
undergoing laparoscopic cholecystectomy or appendectomy under
propofol anesthesia. Clinical Trial Report on Protocol 19.4.318. Merck & Co.,
Inc. 2010.
14. Effect of sugammadex compared with usual care for reversal of
neuromuscular blockade induced by rocuronium on incidence of residual
blockade at PACU entry (Phase 5, Protocol No. P07981 [also known as MK
8616–064]). 2012.
15. A randomized, controlled, parallel-group, double-blind trial of sugammadex
or usual care (neostigmine or spontaneous recovery) for reversal of
rocuronium- or vecuronium-induced neuromuscular blockade in patients
Insinga et al. BMC Anesthesiology  (2016) 16:114 Page 11 of 12
receiving thromboprophylaxis and undergoing hip fracture surgery or joint
(hip/knee) replacement (P07038). 2014.
16. Grintescu I, Mirea L, Ologoiu D, Ungureanu R, Mekauvar S, Vasilescu M.
Comparison of the cost-effectiveness of sugammadex and neostigmine
during general anesthesia for laparascopic cholecystectomy. Br J Anaesth.
2009;103:917.
17. Partownavid P, Romito BT, Ching W, Berry AA, Barkulis CT, Nguyen KP, Jahr
JS. Sugammadex: a comprehensive review of the published human science,
including renal studies. Am J Ther. 2014;22:298–317.
18. Naguib M, Kopman AF, Ensor JE. Neuromuscular monitoring and
postoperative residual curarisation: a meta-analysis. Br J Anaesth.
2007;98:302–16.
19. Kotake Y, Ochiai R, Suzuki T, Ogawa S, Takagi S, Ozaki M, Nakatsuka I, Takeda
J. Reversal with sugammadex in the absence of monitoring did not
preclude residual neuromuscular block. Anesth Analg. 2013;117:345–51.
20. Murphy GS, Szokol JW, Marymont JH, Franklin M, Avram MJ, Vender JS.
Residual paralysis at the time of tracheal extubation. Anesth Analg.
2005;100:1840–5.
21. Murphy GS, Szokol JW, Franklin M, Marymont JH, Avram MJ, Vender JS.
Postanesthesia care unit recovery times and neuromuscular blocking drugs:
a prospective study of orthopedic surgical patients randomized to receive
pancuronium or rocuronium. Anesth Analg. 2004;98:193–200. table.
22. Berg H, Roed J, Viby-Mogensen J, Mortensen CR, Engbaek J, Skovgaard LT,
Krintel JJ. Residual neuromuscular block is a risk factor for postoperative
pulmonary complications. A prospective, randomised, and blinded study of
postoperative pulmonary complications after atracurium, vecuronium and
pancuronium. Acta Anaesthesiol Scand. 1997;41:1095–103.
23. Ledowski T, Hillyard S, O’Dea B, Archer R, Vilas-Boas F, Kyle B. Introduction of
sugammadex as standard reversal agent: impact on the incidence of
residual neuromuscular blockade and postoperative patient outcome.
Indian J Anaesth. 2013;57:46–51.
24. Ledowski T, Falke L, Johnston F, Gillies E, Greenaway M, De Mel A, Tiong
WS, Phillips M. Retrospective investigation of postoperative outcome after
reversal of residual neuromuscular blockade: Sugammadex, neostigmine or
no reversal. Eur J Anaesthesiol. 2014;31:423–9.
25. Rassam S, Sandbythomas M, Vaughan RS, Hall JE. Airway management
before, during and after extubation: a survey of practice in the United
Kingdom and Ireland. Anaesthesia. 2005;60:995–1001.
26. Sakai T, Planinsic RM, Quinlan JJ, Handley LJ, Kim TY, Hilmi IA. The incidence
and outcome of perioperative pulmonary aspiration in a university hospital:
a 4-year retrospective analysis. Anesth Analg. 2006;103:941–7.
27. Warner MA, Warner ME, Weber JG. Clinical significance of pulmonary
aspiration during the perioperative period. Anesthesiology. 1993;78:56–62.
28. Cammu G, De Witte J, De Veylder J, Byttebier G, Vandeput D, Foubert L,
Vandenbroucke G, Deloof T. Postoperative residual paralysis in outpatients
versus inpatients. Anesth Analg. 2006;102:426–9.
29. Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Marymont JH, Vender JS,
Gray J, Landry E, Gupta DK. Intraoperative acceleromyography monitoring
reduces symptoms of muscle weakness and improves quality of recovery in
the early postoperative period. Anesthesiology. 2011;115:946–54.
30. Chambers D, Paulden M, Paton F, Heirs M, Duffy S, Craig D, Hunter J, Wilson
J, Sculpher M, Woolacott N. Sugammadex for the reversal of muscle
relaxation in general anaesthesia: a systematic review and economic
assessment. Health Technol Assess. 2010;14:1–211.
31. Insinga RP, Konstantopoulou T, Athanasakis K, Argyris G. Budget impact of
using sugammadex for the routine reversal of neuromuscular blockade in a
Greek health care setting. ISPOR 15th Annual European Congress. Berlin,
Germany, November 3–7, 2012.
32. Eikermann M, Groeben H, Husing J, Peters J. Accelerometry of adductor
pollicis muscle predicts recovery of respiratory function from neuromuscular
blockade. Anesthesiology. 2003;98:1333–7.
33. Norton M, Xara D, Parente D, Barbosa M, Abelha FJ. Residual neuromuscular
block as a risk factor for critical respiratory events in the post anesthesia
care unit. Rev Esp Anestesiol Reanim. 2013;60:190–6.
34. Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ. A survey of
current management of neuromuscular block in the United States and
Europe. Anesth Analg. 2010;111:110–9.
35. Phillips S, Stewart PA, Bilgin AB. A survey of the management of
neuromuscular blockade monitoring in Australia and New Zealand. Anaesth
Intensive Care. 2013;41:374–9.
36. Parker M, Hattle R, Prejeant D, Stock G. Starting the First Surgical Case on
Time to Cut Delays. Six Sigma case study. February 2010. Available at: www.
isixsigma.com/new-to-six-sigma/dmaic/starting-first-surgical-case-time-cut-
delays. Accessed: 7/9/2015.
37. Jerico MC, Perroca MG, da Penha VC. Measuring quality indicators in the
operating room: cleaning and turnover time. Rev Lat Am Enfermagem.
2011;19:1239–46.
38. Schofield WN, Rubin GL, Piza M, Lai YY, Sindhusake D, Fearnside MR,
Klineberg PL. Cancellation of operations on the day of intended surgery at
a major Australian referral hospital. Med J Aust. 2005;182:612–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Insinga et al. BMC Anesthesiology  (2016) 16:114 Page 12 of 12
